timothy sykes logo

Stock News

Emory University Adopts Microbot Medical’s Liberty Robotic System

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 11/29/2025, 11:17 am ET | 5 min
Emory University Adopts Microbot Medical’s Liberty Robotic System Thumbnail

In this article Last trade Nov, 28 4:59 PM

  • MBOT+7.86%
    MBOT - NASDAQMicrobot Medical Inc.
    $2.47+0.18 (+7.86%)
    Volume:  6.19M
    Float:  63.97M
    $2.35Day Low/High$2.69

Microbot Medical Inc.’s stock surges 7.86% fueled by FDA designation and promising robotic surgery trial data.

Healthcare industry expert:

Analyst sentiment – positive

Microbot Medical Inc. (MBOT) currently shows a challenging market position with several red flags in its financial fundamentals. Despite having a robust current and quick ratio of 27.5 and low leverage ratios, indicating sound liquidity, the company struggles with profitability. Notably, the company’s return on equity (ROE) stands at -52.29% and return on assets (ROA) at -47.96%, reflecting inefficiencies in asset and capital utilization. Additionally, negative cash flow from operations at -$3.84 million and a negative EBIT of -$3.86 million illustrate ongoing financial strain despite a substantial enterprise value of $83.26 million. The emphasis on cash preservation is reflected in a high working capital, but the negative free cash flow and continuous losses suggest ongoing operational challenges.

From a technical analysis perspective, MBOT’s price movements exhibit a significant uptrend, with a notable breakout occurring on Nov 26. This upward movement is supported by a price jump from $1.93 to $2.47 over the course of the reviewed trading days, marking an approximately 28% increase. Observations of strong support at the $1.90 level and significant resistance around the $2.40 mark provide actionable insights for trading strategies. The recent surge in volume accompanying price movement implies growing investor interest, likely influenced by positive news catalysts. Traders might consider a bullish strategy, focusing on buy positions near support levels, with a target toward or beyond prevailing resistance levels after further positive confirmations.

Microbot Medical’s outlook is bolstered by promising developments, particularly the strategic engagement of high-profile institutions like Emory University Hospital with its LIBERTY system. This affiliation signals a pivotal leap in market penetration and technological validation. The recent Limited Market Release and collaborations to establish a robotic program underscore substantial growth potential, aligning well with industry trends favoring innovative medical technologies. Initial adoption by leading healthcare providers confirms the product’s competitive edge in a crowded medical device market. As the company pursues further scalability, maintaining momentum is critical, with resistance at $2.40, now a pivotal test. Optimistically, should these strategic initiatives translate into tangible financial performance enhancements, MBOT is positioned for an upward trajectory.

Candlestick Chart

Weekly Update Nov 24 – Nov 28, 2025: On Saturday, November 29, 2025 Microbot Medical Inc. stock [NASDAQ: MBOT] is trending up by 7.86%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Over recent trading days, Microbot Medical’s stock has experienced a rollercoaster of activity. Starting at $1.92, shares closed at $1.93 on November 24, only to slide downward slightly afterward. However, a remarkable jump occurred on November 26 as it surged to $2.3375, indicating investor enthusiasm spurred by new developments. The subsequent increase to $2.47 on November 28 reflects ongoing market optimism.

Financially, Microbot remains robust. With a total equity of approximately $78.2M, and maintaining a strong current ratio of 27.5, the company’s financial health provides a solid foundation for operational expansion. Despite operating losses evident in the negative earnings per share and comprehensive financial pressures, investment into innovative solutions like the Liberty system illustrates calculated strategic steps toward revenue growth.

More Breaking News

This news impacts the enterprise positively, suggesting potential revenue uplift as the Liberty system gains traction within major U.S. hospitals. The significant rise in share price underlines the market’s expectation of future earnings potential as Microbot’s technologies find broader applications and acceptance.

Conclusion

In summary, Microbot Medical’s strategic advancements and technological deployments are yielding palpable market and operational fruits. The collaboration with Emory University Hospital not only kickstarts the widespread integration of their groundbreaking Liberty system but also underscores the system’s functional suitability and market appeal. Financially, these developments forecast robust revenue channels and strengthen trader confidence, despite past fiscal challenges. As millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.” This philosophy aligns well with Microbot’s methodical approach to strategic growth.

The stock’s positive trajectory, bolstered by credible endorsements and aspirational expansion plans, provides an encouraging outlook. As this technology redefines procedural efficacies in healthcare, Microbot stands poised to maximize on opportunities and ecosystem growth within this burgeoning field. Traders are likely to keep a keen eye on upcoming quarters for performance continuity and strategic updates, making Microbot Medical a compelling narrative in medical technology evolution.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Learn The Formula That Has Created Over 50 Millionaires
TRADE LIKE TIM